Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells

International Journal of Cancer

Volumn 76, Issue 4, 1998, Pages 601-608

  Servais, Patricia ^a   Gulbis, Béatrice ^a,b   Fokan, Dominique ^a   Galand, Paul ^a,c  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYTOSTATIC AGENT; DIMETHYL SULFOXIDE; EDETIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANUMYCIN; MEVINOLIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE MUTATION; MOUSE; NONHUMAN; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; PROTEIN PROCESSING;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL DIVISION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; MICE; ONCOGENE PROTEIN P21(RAS); POLYENES; POLYUNSATURATED ALKAMIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; TIME FACTORS;

EID: 0031960133     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980518)76:4<601::AID-IJC25>3.0.CO;2-8     Document Type: Article

References (23)

1. Bos, J.L., ras oncogenes in human cancer: a review. Cancer Res., 49, 4682-4689 (1989).
2. CLARKE, S., VOGEL, J.P., DESCHENES, R.J. and STOCK, J., Post-translational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxymethyltransferases. Proc. nat. Acad. Sci. (Wash.), 85, 4643-4647 (1988).
3. Cox, A.D., GARCIA, A.M., WESTWICK, J.K., KOWALCZYK, J.J., LEWIS, M.D., BRENNER, D.A. and DER, C.J., The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. biol. Chem., 269, 19203-19206 (1994).
4. DALTON, M.B., FANTLE, K.S., BECHTOLD, H.A., DEMAIO, L., EVANS, R.M., KRYSTOSEK, A. and SINENSKY, M., The farnesyl-protein-transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21 -ras but does not affect their function or localization. Cancer Res., 55, 3295-3304 (1995).
5. GARCIA, A.M., ROWELL, C. ACKERMANN, K., KOWALCZYK, J.J. and LEWIS, M.D., Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J. biol. Chem., 268, 18415-18418 (1993).
6. GIBBS, J.B., OLIFF, A. and KOHL, N.E., Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell, 77, 175-178 (1994).
7. GOLDSTEIN, J.L., BROWN, M.S., STRADLEY, S.J., REISS, Y. and GIERASCH, L.M., Non-farnesylated tetrapeptides inhibitors of protein farnesyltransferase. J. biol. Chem., 266, 15575-15578 (1991).
8. GULBIS, B. and GALAND, P., Relative steady-state expression of the different post-translational products of p21H-ras from normal rat tissue. A 2D-Western-immunoblot study. Life Sci., 54, 1747-1756 (1994).
9. GUTTIEREZ, L., MAGEE, A., MARSHALL, C. and HANCOCK, J., Posttranslational processing of p21 ras is two-step and involves carboxylation and carboxy-terminal proteolysis. EMBO J., 8, 1093-1098 (1989).
10. HANCOCK, J.F., CADWALLADER, K., PATERSON, H. and MARSHALL, C.J., A CAAX or a CAAL motif and a second signal are sufficient for plasma-membrane targeting of ras proteins. EMBO J., 10, 1093-1098 (1991).
11. HARA, M., KAZUHITO, A., AKINAGA, S., OKABE, M., NAKANO, R.G., WOOD, D., UH, M. and TAMANOI, F., Identification of ras farnesyltansferase inhibitors by microbial screening. Proc. nat. Acad. Sci. (Wash.), 90, 2281-2285 (1993).
12. ITO, T., KAWATA, S., TAMURA, S., IGURA, T., NAGASE, T., MIYAGAWA, J., YAMAZAKI, E., ISHIGURO, H. and MATSUZAWA, Y., Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl: protein transferase inhibitor. Jap. J. Cancer Res., 87, 113-116 (1996).
13. JAMES, G.L., GOLDSTEIN, J.L., BROWN, M.S., RAWSON, T.E., SOHERS, T.C., MCDOWELL, R.S., CROWLEY, C.W., LUCAS, B.K., LEVINSON, A.D. and MARSTERS, J.C., Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science, 260, 1937-1942 (1993).
14. KATO, K., COX, A.D., HISAKA, M.M., GRAHAM, S.M. and DER, C.J., Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc. nat. Acad. Sci. (Wash.), 89, 6403-6407 (1992).
15. KOHL, N.E., MOSSER, S.D., DE SOLMS, J., GIUCIANI, E.A., POMPCIANO, D.L., GRAHAM, S.L., SMITH, R.L., SCOLNICK, E.M., OLIFF, A. and GIBBS, J.B., Selective inhibition of ras-dependent transformation by a farnesyl-transferase inhibitors. Science. 260, 1934-1937 (1993).
16. LEBOWITZ, P.F., DAVIDE, J.P. and PRENDERGAST, G.C., Evidence that farnesylase inhibitors suppress ras transformation by interfering with Rho activity. Mol. cell. Biol., 15, 6613-6622 (1995).
17. LERNER, E.C., QIAN, Y., BLASKOVICH, M.A., FOSSUM, R.D., VOGT, A., SUN, J., COX, A.D., DER, C.J., HAMILTON, A.D. and SEBTI, S.M., Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J. biol. Chem., 270, 26802-26806 (1995).
18. MANNE, V. and 16 OTHERS, Bi-substrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras-transformed cells. Oncogene, 10, 1763-1773 (1995).
19. NAGASE, T., KAWATA, S., TAMURA, S., MATSUDA, Y., INUI, Y., YAMASAKI, E., ISHIGURO, H., ITO, T. and MATSUZAWA, Y., Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl-protein-transferase inhibitor: a preferential suppression of ras farnesylation. Int. J. Cancer, 65, 620-626 (1996).
20. PATEL, D.V. and 12 OTHERS, Phospninyl-acid-based bi-substrate analog inhibitors of farnesyl protein transferase. J. med. Chem., 38, 435-442 (1995).
21. PRENDERGAST, G.G., DAVIDE, J.P., DE SOLMS, S.J., GIULIANI, E., GRAHAM, S., GIBBS. J.B., OLIFF, A. and KOHL, N.E., Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. cell. Biol., 14, 4193-4202 (1994).
22. TAMANOI, E. Inhibitors of Ras farnesyltransterases. Trends biochem. Sci., 18, 349-353 (1993).
23. VOGT, A., QIAN, Y., BLASTOKOVICH, M.A., FOSSUM, R.D., HAMILTON, A.D. and SEBTI, S.M., A non-peptide mimetic of ras-CAAX: selective inhibition of farnesyltransferase and ras processing. J. biol. Chem., 270, 660-664 (1995).